Product Information
CLONAZEPAM 0.125 MG ODT is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.5199 per EA under NDC 62332036406. Its NADAC has been published 360 times since Nov 13, 2019.
FDA first approved this application on Jun 28, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.125 mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332036406
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA211033FDA Approved
6/28/2019
TE Code
AB
On Market Since
7/1/2019
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 0.125 MG ODT has been published 360 times since Nov 13, 2019, and over the history we have for it it has declined 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5199 per EA |
|---|---|
| All-time high | $0.7914 (Jan 10, 2024) |
| All-time low | $0.4221 (Jul 17, 2024) |
| 52-week high | $0.6134 |
| 52-week low | $0.5038 |
| Median price | $0.5915 |
| Average price | $0.5948 |
| Largest weekly change | +47.8% (Aug 21, 2024) |
| Weeks tracked | 360 |
| Tracking since | Nov 13, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CLONAZEPAM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CLONAZEPAM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 0.125 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 0.125 MG ODT, manufactured by Alembic Pharmaceuticals Inc., is $0.5199 per EA (NDC 62332036406), effective Sep 30, 2026.
How has the price of CLONAZEPAM 0.125 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 0.125 MG ODT has declined 4.4%. It has been tracked across 360 weekly CMS publications since Nov 13, 2019.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 0.125 MG ODT?
Since Nov 13, 2019, the NADAC for CLONAZEPAM 0.125 MG ODT has ranged from a low of $0.4221 (Jul 17, 2024) to a high of $0.7914 (Jan 10, 2024), with a median of $0.5915 per EA.
Are there cheaper alternatives to CLONAZEPAM 0.125 MG ODT?
No other NADAC-published product currently shares the active ingredient and strength of CLONAZEPAM 0.125 MG ODT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLONAZEPAM 0.125 MG ODT?
CLONAZEPAM 0.125 MG ODT (NDC 62332036406) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.